2 July 2025 in European Journal of Pediatrics
1 January 2024 in TURKISH JOURNAL OF MEDICAL SCIENCES
Data on the prevalence of allergic diseases in children with proven drug allergies are limited. We aim to evaluate thefrequency of allergic comorbidity in children with proven common drug allergies.Materials and methods: Children with drug hypersensitivity confirmed by diagnostic allergy tests at our center between January 2010and December 2020 were screened retrospectively. Patients with the most common drug allergies (due to antibiotics, nonsteroidalantiinflammatory drugs [NSAIDs], and antiepileptic drugs) were selected for analysis. Age, sex, the culprit drug, initial reactioncharacteristics, diagnostic test results, and the study physician who diagnosed concomitant allergic diseases were noted.Results: A total of 168 patients (boys, 51.2%) with a median age of 12 years (IQR = 8–16.3) were included in the study. The culprit drugwas an antibiotic in 63% (n = 106), NSAID in 25% (n = 42) and anticonvulsant in 11.9 % (n = 20) of the patients. Drug hypersensitivityreactions were immediate in 74.4 % (n = 125) and delayed in 25.6 % (n = 43) of the patients. Seventy-five patients (44.6 %) had at leastone allergic disease, most commonly rhinitis (27.3 %, n = 46) or asthma (25 %, n = 42). Fifty-five patients underwent skin prick testswith aeroallergens, producing a positive result in 60% (n = 31). The prevalence of allergic disease was not differing according to theculprit drug. The frequency of developing at least one concomitant allergic disease was 47.2% (n = 50/106) for antibiotic hypersensitivity,52.4% (n = 22/42) for NSAID hypersensitivity, and 15% (n = 3/20) for anticonvulsant hypersensitivity (p < 0.00).Immediate drug hypersensitivity reactions were more frequent in children who had allergic diseases (80 % vs. 64.5 %; p = 0.027).Conclusion: Nearly half (44.6%) of the children with proven drug hypersensitivity had concomitant allergic diseases and immediatereactions were more common in this group. Children evaluated for drug hypersensitivity should be assessed for other allergic diseases.
2 February 2026 in Pediatric Allergy and Immunology
1 April 2026 in Pediatric Allergy and Immunology
Background and Objective: Adverse drug reactions (ADRs) are a serious public health problem. This study aimed to evaluate reaction characteristics and diagnostic test results in pediatric patients in whom suspected drug allergy was confirmed by in vivo diagnostic tests. Methods: Children who presented with suspected drug allergy between January 1, 2013 and January 1, 2023 in Ankara, Türkiye and underwent in vivo diagnostic testing were included in the study. Patients with positive diagnostic tests were compared with those whose tests resulted negative. Results: Over the 10‐year study period, 1818 patients presented with suspected drug allergy and were followed up for 1892 presumed drug‐associated hypersensitivity reactions. A total of 4532 in vivo diagnostic tests were performed with the 2082 suspect drugs implicated in these reactions. Drug allergy was confirmed by in vivo diagnostic tests in 225 patients (12.5%). A total of 242 (5.3%) tests resulted positive, with positivity rates of 1.3% for skin prick tests (SPTs), 2.7% for intradermal tests (IDTs), 19.4% for patch tests and 8.5% for drug provocation tests (DPTs). Among patients with positive in vivo diagnostic test results, the most common suspect drugs were antibiotics (53.9%), followed by non‐steroidal anti‐inflammatory drugs (NSAIDs; 31.5%) and antiepileptic drugs (7.4%). There was no significant difference between patients with positive and negative diagnostic test results in terms of sex (50.2% vs. 53.4%, p = .36). However, age at reaction was significantly higher among patients with positive diagnostic test results (92 vs. 49 months, p < .001). The prevalence of antibiotics (53.9% vs. 78.2%) was significantly higher and the rates of NSAIDs (31.5% vs. 15%) was significantly lower in the group with negative diagnostic test results ( p < .001 for both). In both groups, the most common clinical manifestations were cutaneous symptoms (93.3% and 94.5%, p = .44). Respiratory symptoms and a history of anaphylaxis were more frequent in the group with positive test results. Conclusion: The use of standardized systematic approaches for the diagnosis and management of drug hypersensitivity reactions can potentially improve outcomes, and diagnostic tests should be performed in patients with no contraindications.
12 July 2022 in Journal of Dermatological Treatment
Atopic Dermatitis (AD) is a chronic, recurrent and inflammatory skin disease experienced mostly in childhood. Chronicity of the disease, relapses, constant need of regular skin care causes seeking ...
6 June 2022 in Journal of Tropical Pediatrics
Objective: Hereditary angioedema (HAE) is clinically characterized by recurrent attacks of angioedema. This study evaluated the clinical findings and examination results of patients admitted due to angioedema who then underwent a diagnostic test for HAE. The study aimed to assess the contribution of laboratory findings to the diagnostic process and to determine clinicians’ level of awareness regarding the differential diagnosis of angioedema and the appropriate laboratory tests. Methods: Pediatric patients suspected to have HAE based on the presence of angioedema and screened for C1 esterase inhibitor levels and/or function were included in the study. Results: A total of 136 patients were evaluated for a preliminary diagnosis of HAE in the presence of angioedema. Angioedema was accompanied by urticaria in 65 patients (47.7%) and itching in 24 patients (17.6%). Patients were evaluated using laboratory tests, C4 levels were studied in 124 patients (91.1%) and were found to be within normal reference limits. C1 esterase inhibitor levels were studied in all patients and were found to be within normal limits. C1 esterase inhibitor function was also studied in 101 patients (74.2%) and was found to be within normal limits. Discussion: It was concluded that clinicians keep HAE in mind when encountering angioedema, but that increasing their knowledge of clinical findings that assist in differential diagnosis among angioedema types would be useful. The study authors would like to emphasize that this topic should be included in the specialty training curriculum to raise the awareness of clinicians, especially pediatricians, about clinical HAE findings and the algorithmic approach to the differential diagnosis of angioedema.